Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

KEVIN D CANNON

Allopathic & Osteopathic Physicians Hospitalist

NPI
1700897022
CMS profile
122867
Location
WILMINGTON, NC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$58.19

2 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

Nature of paymentAmountRecords
Education $32.27 1
Food and Beverage $25.92 1

By paying entity

PY2022 · entire year · sorted by reported total

Paying entityAmountRecords
Novo Nordisk Inc $32.27 1
Boehringer Ingelheim Pharmaceuticals, Inc. $25.92 1

Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

KEVIN D CANNON

NPI 1700897022 · CMS profile ID 122867

Allopathic & Osteopathic Physicians / Hospitalist

WILMINGTON, NC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1700897022?year=2022&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
KEVIN D CANNON, NPI 1700897022, CMS profile ID 122867. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1700897022?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). KEVIN D CANNON, NPI 1700897022, CMS profile ID 122867. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1700897022?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
KEVIN D CANNON, NPI 1700897022, CMS profile ID 122867, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1700897022?year=2022&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

2 matching records · $58.19 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 2 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–2 of 2.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Boehringer Ingelheim Pharmaceuticals, Inc. $25.9208/03/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 887506015 CMS
Novo Nordisk Inc $32.2706/08/2022 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 898661569 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $3,301.48 16
PY2021 $20.00 1
PY2022 $58.19 2
PY2023 $1,400.30 14
PY2025 $116.03 2

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2021, 2022, 2023, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2021 , PY2022 , PY2023 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $3,200.00 1
PY2025 Principal investigator $6,407,903.58 738
PY2024 Recipient $12,299.41 13
PY2024 Principal investigator $7,058,469.69 390
PY2023 Recipient $3,980.00 2
PY2023 Principal investigator $7,125,617.33 899
PY2022 Recipient $9,082.00 12
PY2022 Principal investigator $6,929,547.49 979
PY2021 Recipient $14,312.20 61
PY2021 Principal investigator $9,361,495.59 2,459
PY2020 Recipient $233.41 1
PY2020 Principal investigator $5,812,787.31 750
PY2019 Principal investigator $4,820,055.08 826

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

403 records in PY2024

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 PFIZER INC. $164.40 12/31/2024 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1130968908
Recipient PFIZER INC. $3,200.00 12/30/2024 Covered Recipient Physician NONCOVERED PRODUCT CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1130898013
Principal investigator 1 ModernaTX, Inc. $399,477.62 12/23/2024 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled, Case-drivenStudy to Investigate the Safety, Efficacy, and Immunogenicity of mRNA-1010 Candidate Seasonal Influenza Vaccine Compared with a Licensed Inactivated Seasonal Influenza Vaccine in Adults 50 Years of Age No dispute reported 06/30/2026 1147191506
Principal investigator 1 ModernaTX, Inc. $119,433.22 12/23/2024 Non-covered Recipient Entity
ACCELLACARE US INC
A PHASE 3, RANDOMIZED, OBSERVER-BLINDED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF MRNA-1403, A MULTIVALENT CANDIDATE VACCINE TO PREVENT NOROVIRUS ACUTE GASTROENTERITIS IN ADULTS 18 YEARS OF AGE No dispute reported 06/30/2026 1147191516
Principal investigator 1 ModernaTX, Inc. $200,730.60 12/19/2024 Non-covered Recipient Entity
ACCELLACARE US INC
A PHASE 3, RANDOMIZED, OBSERVER-BLINDED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF MRNA-1403, A MULTIVALENT CANDIDATE VACCINE TO PREVENT NOROVIRUS ACUTE GASTROENTERITIS IN ADULTS 18 YEARS OF AGE No dispute reported 06/30/2026 1147191510
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $6,484.05 12/18/2024 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity No dispute reported 06/30/2026 1082449818
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,713.75 12/18/2024 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity No dispute reported 06/30/2026 1082449858
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,000.00 12/18/2024 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity No dispute reported 06/30/2026 1082449892
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $578.36 12/18/2024 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity No dispute reported 06/30/2026 1082449894
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $7,238.25 12/18/2024 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity No dispute reported 06/30/2026 1082449926
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,282.85 12/18/2024 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity No dispute reported 06/30/2026 1082449958
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $22,409.73 12/18/2024 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity No dispute reported 06/30/2026 1082450024
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,299.48 12/18/2024 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity No dispute reported 06/30/2026 1082450028
Principal investigator 1 ModernaTX, Inc. $75.13 12/12/2024 Non-covered Recipient Entity
ACCELLACARE US INC
A PHASE 3, RANDOMIZED, OBSERVER-BLINDED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF MRNA-1403, A MULTIVALENT CANDIDATE VACCINE TO PREVENT NOROVIRUS ACUTE GASTROENTERITIS IN ADULTS 18 YEARS OF AGE No dispute reported 06/30/2026 1147191498
Principal investigator 1 BioNTech SE $4,948.00 12/10/2024 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1150665549
Principal investigator 1 PFIZER INC. $3,464.76 12/10/2024 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1130968732
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $236.25 12/10/2024 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity No dispute reported 06/30/2026 1082447896
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,050.00 12/10/2024 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity No dispute reported 06/30/2026 1082447918
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $500.00 12/10/2024 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity No dispute reported 06/30/2026 1082447942
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,500.00 12/10/2024 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity No dispute reported 06/30/2026 1082447944
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $6,206.55 12/10/2024 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity No dispute reported 06/30/2026 1082447994
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,083.94 12/10/2024 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity No dispute reported 06/30/2026 1082448028
Principal investigator 1 PFIZER INC. $1,665.65 12/05/2024 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 1130968914
Principal investigator 1 BioNTech SE $96.00 12/03/2024 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1150665555
Principal investigator 1 BioNTech SE $3,000.00 12/03/2024 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1150665563
Principal investigator 1 BioNTech SE $3,324.00 12/03/2024 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1150665578
Principal investigator 1 ModernaTX, Inc. $75.13 12/03/2024 Non-covered Recipient Entity
ACCELLACARE US INC
A PHASE 3, RANDOMIZED, OBSERVER-BLINDED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF MRNA-1403, A MULTIVALENT CANDIDATE VACCINE TO PREVENT NOROVIRUS ACUTE GASTROENTERITIS IN ADULTS 18 YEARS OF AGE No dispute reported 06/30/2026 1147191496
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $31,206.06 12/03/2024 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity No dispute reported 06/30/2026 1082446660
Principal investigator 1 Novo Nordisk AS $4,812.50 12/02/2024 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 1096793705
Principal investigator 1 ModernaTX, Inc. $47,329.10 11/27/2024 Non-covered Recipient Entity
ACCELLACARE US INC
A PHASE 3, RANDOMIZED, OBSERVER-BLINDED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF MRNA-1403, A MULTIVALENT CANDIDATE VACCINE TO PREVENT NOROVIRUS ACUTE GASTROENTERITIS IN ADULTS 18 YEARS OF AGE No dispute reported 06/30/2026 1147191484
Principal investigator 1 BioNTech SE $954.00 11/26/2024 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1150665559
Principal investigator 1 ModernaTX, Inc. $88.79 11/26/2024 Non-covered Recipient Entity
ACCELLACARE US INC
A PHASE 3, RANDOMIZED, OBSERVER-BLINDED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF MRNA-1403, A MULTIVALENT CANDIDATE VACCINE TO PREVENT NOROVIRUS ACUTE GASTROENTERITIS IN ADULTS 18 YEARS OF AGE No dispute reported 06/30/2026 1147191482
Recipient PFIZER INC. $3,200.00 11/26/2024 Covered Recipient Physician NONCOVERED PRODUCT CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1130899325
Principal investigator 1 PFIZER INC. $4,908.41 11/26/2024 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1130983628
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $23,909.72 11/26/2024 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity No dispute reported 06/30/2026 1082445870
Principal investigator 1 ModernaTX, Inc. $81.96 11/21/2024 Non-covered Recipient Entity
ACCELLACARE US INC
A PHASE 3, RANDOMIZED, OBSERVER-BLINDED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF MRNA-1403, A MULTIVALENT CANDIDATE VACCINE TO PREVENT NOROVIRUS ACUTE GASTROENTERITIS IN ADULTS 18 YEARS OF AGE No dispute reported 06/30/2026 1147191480
Principal investigator 1 PFIZER INC. $816.34 11/21/2024 Non-covered Recipient Entity
Accellacare US Inc
AN INTERVENTIONAL PHASE 23 ADAPTIVE MULTICENTER RANDOMIZED DOUBLEBLIND STUDY TO INVESTIGATE EFFICACY AND SAFETY OF ORAL SISUNATOVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULTS WITH RESPIRATORY SYNCYTIAL VIRUS INFECTION WHO ARE AT RISK OF PROGRESSION TO SEVERE ILLNESS No dispute reported 06/30/2026 1130983125
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,041.00 11/21/2024 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity No dispute reported 06/30/2026 1082445394
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,500.00 11/21/2024 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity No dispute reported 06/30/2026 1082445424
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,000.00 11/21/2024 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity No dispute reported 06/30/2026 1082445446
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $7,422.00 11/21/2024 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity No dispute reported 06/30/2026 1082445472
Principal investigator 1 Novo Nordisk AS $1,529.24 11/20/2024 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 1096761871
Principal investigator 1 BioNTech SE $95.90 11/19/2024 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1150665545
Principal investigator 1 BioNTech SE $12,926.00 11/19/2024 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1150665567
Principal investigator 1 BioNTech SE $97.27 11/19/2024 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1150665593
Principal investigator 1 ModernaTX, Inc. $88.79 11/19/2024 Non-covered Recipient Entity
ACCELLACARE US INC
A PHASE 3, RANDOMIZED, OBSERVER-BLINDED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF MRNA-1403, A MULTIVALENT CANDIDATE VACCINE TO PREVENT NOROVIRUS ACUTE GASTROENTERITIS IN ADULTS 18 YEARS OF AGE No dispute reported 06/30/2026 1147191478
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $26,772.26 11/19/2024 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity No dispute reported 06/30/2026 1082445106
Principal investigator 1 ModernaTX, Inc. $81.96 11/13/2024 Non-covered Recipient Entity
ACCELLACARE US INC
A PHASE 3, RANDOMIZED, OBSERVER-BLINDED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF MRNA-1403, A MULTIVALENT CANDIDATE VACCINE TO PREVENT NOROVIRUS ACUTE GASTROENTERITIS IN ADULTS 18 YEARS OF AGE No dispute reported 06/30/2026 1147191476
Principal investigator 1 PFIZER INC. $34,226.55 11/13/2024 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 1130982584
Principal investigator 1 PFIZER INC. $3,353.90 11/13/2024 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 1130983131
Principal investigator 1 PFIZER INC. $4,000.00 11/13/2024 Non-covered Recipient Entity
Accellacare US Inc
AN INTERVENTIONAL PHASE 23 ADAPTIVE MULTICENTER RANDOMIZED DOUBLEBLIND STUDY TO INVESTIGATE EFFICACY AND SAFETY OF ORAL SISUNATOVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULTS WITH RESPIRATORY SYNCYTIAL VIRUS INFECTION WHO ARE AT RISK OF PROGRESSION TO SEVERE ILLNESS No dispute reported 06/30/2026 1130983615
Principal investigator 1 BioNTech SE $6,218.00 11/12/2024 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1150665576
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $14,680.25 11/12/2024 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity No dispute reported 06/30/2026 1082444158
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $26,514.00 11/12/2024 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity No dispute reported 06/30/2026 1082444170
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $784.08 11/12/2024 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity No dispute reported 06/30/2026 1082444182
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $778.95 11/12/2024 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity No dispute reported 06/30/2026 1082444188
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,104.00 11/12/2024 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity No dispute reported 06/30/2026 1082444200
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $35,078.95 11/12/2024 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity No dispute reported 06/30/2026 1082444252
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.31 11/12/2024 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity No dispute reported 06/30/2026 1082444272
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $490.05 11/12/2024 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity No dispute reported 06/30/2026 1082444300
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $6,017.00 11/12/2024 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity No dispute reported 06/30/2026 1082444302
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $14,601.00 11/12/2024 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity No dispute reported 06/30/2026 1082444316
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $13,905.00 11/12/2024 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity No dispute reported 06/30/2026 1082444336
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,710.00 11/12/2024 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity No dispute reported 06/30/2026 1082444346
Principal investigator 1 PFIZER INC. $2,456.77 11/08/2024 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1130983119
Principal investigator 1 BioNTech SE $10,922.00 11/05/2024 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1150665571
Principal investigator 1 PFIZER INC. $666.64 11/05/2024 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 12 RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST VARICELLA ZOSTER VIRUS IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1130983622
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $295,501.75 11/05/2024 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity No dispute reported 06/30/2026 1082443658
Principal investigator 1 AstraZeneca Pharmaceuticals LP $12,000.00 10/31/2024 Non-covered Recipient Entity
ACCELLACARE
A Phase II Randomised Double blind Placebo controlled Study to Evaluate the Efficacy Safety and Tolerability of AZD5004 in Participants living with Obesity or Overweight with Comorbidity No dispute reported 06/30/2026 1110845189
Principal investigator 1 ModernaTX, Inc. $204.90 10/31/2024 Non-covered Recipient Entity
ACCELLACARE US INC
A PHASE 3, RANDOMIZED, OBSERVER-BLINDED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF MRNA-1403, A MULTIVALENT CANDIDATE VACCINE TO PREVENT NOROVIRUS ACUTE GASTROENTERITIS IN ADULTS 18 YEARS OF AGE No dispute reported 06/30/2026 1147191466
Principal investigator 1 BioNTech SE $132.00 10/30/2024 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1150665541
Principal investigator 1 BioNTech SE $7,263.00 10/30/2024 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1150665543
Principal investigator 1 BioNTech SE $284.65 10/30/2024 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1150665551
Principal investigator 1 BioNTech SE $522.42 10/30/2024 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1150665588
Principal investigator 1 BioNTech SE $4,255.00 10/22/2024 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1150665547
Principal investigator 1 PFIZER INC. $73,035.00 10/22/2024 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 1130992715
Principal investigator 1 ModernaTX, Inc. $249.45 10/16/2024 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled, Case-drivenStudy to Investigate the Safety, Efficacy, and Immunogenicity of mRNA-1010 Candidate Seasonal Influenza Vaccine Compared with a Licensed Inactivated Seasonal Influenza Vaccine in Adults 50 Years of Age No dispute reported 06/30/2026 1147191468
Principal investigator 1 Novo Nordisk AS $21,397.45 10/16/2024 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9932-4954 No dispute reported 06/30/2026 1097093769
Principal investigator 1 Novo Nordisk AS $3,000.00 10/16/2024 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9932-4954 No dispute reported 06/30/2026 1097609670
Principal investigator 1 BioNTech SE $13,195.00 10/15/2024 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1150665557
Principal investigator 1 ModernaTX, Inc. $399.12 10/14/2024 Non-covered Recipient Entity
ACCELLACARE US INC
A PHASE 3, RANDOMIZED, OBSERVER-BLINDED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF MRNA-1403, A MULTIVALENT CANDIDATE VACCINE TO PREVENT NOROVIRUS ACUTE GASTROENTERITIS IN ADULTS 18 YEARS OF AGE No dispute reported 06/30/2026 1147191464
Principal investigator 1 BioNTech SE $15,992.00 10/10/2024 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1150665584
Principal investigator 1 BioNTech SE $234.42 10/09/2024 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1150665553
Principal investigator 1 PFIZER INC. $3,000.00 10/05/2024 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 2B DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED PARALLEL GROUP DOSE RANGING STUDY TO EVALUATE VIROLOGICAL RESPONSE AND SAFETY OF ORAL PF07817883 IN NONHOSPITALIZED SYMPTOMATIC ADULT PARTICIPANTS WITH COVID19 No dispute reported 06/30/2026 1130983424
Principal investigator 1 PFIZER INC. $16,877.38 10/05/2024 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1130992861
Principal investigator 1 BioNTech SE $600.00 10/04/2024 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1150665561
Principal investigator 1 BioNTech SE $5,461.00 10/04/2024 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1150665565
Principal investigator 1 BioNTech SE $11,158.00 10/04/2024 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1150665582
Recipient PFIZER INC. $620.00 09/29/2024 Covered Recipient Physician NONCOVERED PRODUCT CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1130898359
Principal investigator 1 PFIZER INC. $875.00 09/25/2024 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 12 RANDOMIZED DOUBLEBLIND TRIAL OF THE SAFETY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS 18 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 1131016033
Principal investigator 1 BioNTech SE $3,285.00 09/24/2024 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1150665507
Principal investigator 1 Novo Nordisk AS $2,080.19 09/20/2024 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 1096869509
Principal investigator 1 Novo Nordisk AS $400.00 09/20/2024 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9932-4954 No dispute reported 06/30/2026 1097893229
Principal investigator 1 BioNTech SE $693.00 09/18/2024 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1150665505
Principal investigator 1 BioNTech SE $96.00 09/18/2024 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1150665527
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $433,682.84 09/18/2024 Non-covered Recipient Entity
Pmg Research
phase III efficacy for obesity - with T2DM No dispute reported 06/30/2026 1101071833
Principal investigator 1 PFIZER INC. $35,914.86 09/11/2024 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1131016027
Principal investigator 1 BioNTech SE $9,300.00 09/10/2024 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1150665515
Principal investigator 1 PFIZER INC. $4,333.50 09/06/2024 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 12 RANDOMIZED DOUBLEBLIND TRIAL OF THE SAFETY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS 18 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 1131018498
Principal investigator 1 BioNTech SE $5,184.00 09/03/2024 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1150665499
Principal investigator 1 ModernaTX, Inc. $598.68 08/29/2024 Non-covered Recipient Entity
ACCELLACARE RESEARCH WILMINGTON
A Phase 3, Randomized, Observer-blind, Active-controlled, Case-drivenStudy to Investigate the Safety, Efficacy, and Immunogenicity of mRNA-1010 Candidate Seasonal Influenza Vaccine Compared with a Licensed Inactivated Seasonal Influenza Vaccine in Adults 50 Years of Age No dispute reported 06/30/2026 1147180899
Principal investigator 1 PFIZER INC. $38,854.00 08/28/2024 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 1131031876
Principal investigator 1 PFIZER INC. $26,001.00 08/28/2024 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 12 RANDOMIZED DOUBLEBLIND TRIAL OF THE SAFETY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS 18 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 1131032490
Principal investigator 1 BioNTech SE $5,461.00 08/27/2024 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1150665539
Recipient PFIZER INC. $3,200.00 08/27/2024 Covered Recipient Physician RSV VACCINE PROT SUBUNIT PREF 2V CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1130898009
Principal investigator 1 PFIZER INC. $500.00 08/27/2024 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 MASTER PROTOCOL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS AT HIGH RISK OF SEVERE RSV DISEASE No dispute reported 06/30/2026 1131031870
Principal investigator 1 Novo Nordisk AS $10,113.04 08/23/2024 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 1096808138
Principal investigator 1 PFIZER INC. $679.79 08/23/2024 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 12 RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST VARICELLA ZOSTER VIRUS IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1131033138
Principal investigator 1 Novo Nordisk AS $3,000.00 08/21/2024 Non-covered Recipient Entity
PMG RES OF WILMINGTON, LLC
NN9535-4984 No dispute reported 06/30/2026 1096863476
Principal investigator 1 PFIZER INC. $9,350.25 08/21/2024 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1131033133
Principal investigator 1 BioNTech SE $10,506.00 08/19/2024 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1150665497
Principal investigator 1 Novo Nordisk AS $6,080.40 08/19/2024 Non-covered Recipient Entity
PMG RES OF WILMINGTON, LLC
NN9535-4984 No dispute reported 06/30/2026 1096857743
Principal investigator 1 PFIZER INC. $5,000.00 08/16/2024 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 MASTER PROTOCOL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS AT HIGH RISK OF SEVERE RSV DISEASE No dispute reported 06/30/2026 1131033747
Principal investigator 1 PFIZER INC. $2,039.37 08/14/2024 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 12 RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST VARICELLA ZOSTER VIRUS IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1131031882
Principal investigator 1 PFIZER INC. $156,840.49 08/14/2024 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1131033393
Principal investigator 1 PFIZER INC. $645.00 08/14/2024 Non-covered Recipient Entity
Accellacare US Inc
AN INTERVENTIONAL PHASE 23 ADAPTIVE MULTICENTER RANDOMIZED DOUBLEBLIND STUDY TO INVESTIGATE EFFICACY AND SAFETY OF ORAL SISUNATOVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULTS WITH RESPIRATORY SYNCYTIAL VIRUS INFECTION WHO ARE AT RISK OF PROGRESSION TO SEVERE ILLNESS No dispute reported 06/30/2026 1131033565
Principal investigator 1 PFIZER INC. $25,381.50 08/14/2024 Non-covered Recipient Entity
Accellacare US Inc
AN INTERVENTIONAL RANDOMIZED ACTIVECONTROLLED PHASE 23 STUDY TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B RNABASED VACCINE CANDIDATES AS A BOOSTER DOSE IN COVID19 VACCINEEXPERIENCED HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1131033571
Principal investigator 1 BioNTech SE $5,184.00 08/13/2024 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1150665501
Principal investigator 1 BioNTech SE $66.00 08/13/2024 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1150665529
Principal investigator 1 BioNTech SE $3,285.00 08/07/2024 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1150665495
Principal investigator 1 BioNTech SE $385.00 08/07/2024 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1150665503
Principal investigator 1 BioNTech SE $396.00 08/07/2024 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1150665511
Principal investigator 1 BioNTech SE $96.00 08/07/2024 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1150665523
Principal investigator 1 BioNTech SE $66.00 08/07/2024 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1150665535
Principal investigator 1 PFIZER INC. $76,476.35 08/06/2024 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 12 RANDOMIZED DOUBLEBLIND TRIAL OF THE SAFETY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS 18 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 1131032998
Principal investigator 1 PFIZER INC. $34,544.63 08/06/2024 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1131033387
Principal investigator 1 PFIZER INC. $63,787.50 08/06/2024 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 1131033739
Principal investigator 1 BioNTech SE $4,352.00 08/01/2024 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1150665519
Principal investigator 1 BioNTech SE $3,465.00 08/01/2024 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1150665531
Recipient Regeneron Pharmaceuticals, Inc. $15.10 07/26/2024 Covered Recipient Physician A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity No dispute reported 06/30/2026 1082393398
Recipient Regeneron Pharmaceuticals, Inc. $44.50 07/26/2024 Covered Recipient Physician A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity No dispute reported 06/30/2026 1082393400
Recipient Regeneron Pharmaceuticals, Inc. $60.40 07/26/2024 Covered Recipient Physician A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity No dispute reported 06/30/2026 1082393402
Recipient Regeneron Pharmaceuticals, Inc. $233.63 07/26/2024 Covered Recipient Physician A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity No dispute reported 06/30/2026 1082393404
Recipient Regeneron Pharmaceuticals, Inc. $305.89 07/26/2024 Covered Recipient Physician A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity No dispute reported 06/30/2026 1082393406
Recipient Regeneron Pharmaceuticals, Inc. $32.57 07/25/2024 Covered Recipient Physician A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity No dispute reported 06/30/2026 1082393394
Recipient Regeneron Pharmaceuticals, Inc. $128.98 07/25/2024 Covered Recipient Physician A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity No dispute reported 06/30/2026 1082393396
Principal investigator 1 BioNTech SE $15,295.00 07/23/2024 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1150665493
Principal investigator 1 Novo Nordisk AS $300.00 07/22/2024 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 1096855643
Principal investigator 1 Novo Nordisk AS $7,580.45 07/22/2024 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 1096856586
Principal investigator 1 Novavax Inc $25,680.00 07/18/2024 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Matrix-M1 Adjuvant in Adult Participants older than or equal to 18 Years With a Pediatric Expansion in Adolescents (12 to younger than 18 Years) No dispute reported 06/30/2026 1123376635
Principal investigator 1 PFIZER INC. $2,073.60 07/18/2024 Non-covered Recipient Entity
Accellacare
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 1130916779
Principal investigator 1 PFIZER INC. $2,454.45 07/17/2024 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 2B DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED PARALLEL GROUP DOSE RANGING STUDY TO EVALUATE VIROLOGICAL RESPONSE AND SAFETY OF ORAL PF07817883 IN NONHOSPITALIZED SYMPTOMATIC ADULT PARTICIPANTS WITH COVID19 No dispute reported 06/30/2026 1130991879
Principal investigator 1 PFIZER INC. $11,727.50 07/17/2024 Non-covered Recipient Entity
Accellacare US Inc
AN INTERVENTIONAL RANDOMIZED ACTIVECONTROLLED PHASE 23 STUDY TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B RNABASED VACCINE CANDIDATES AS A BOOSTER DOSE IN COVID19 VACCINEEXPERIENCED HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1131042444
Principal investigator 1 BioNTech SE $5,738.00 07/16/2024 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1150665533
Principal investigator 1 PFIZER INC. $5,637.79 07/16/2024 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 12 RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST VARICELLA ZOSTER VIRUS IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1131043296
Principal investigator 1 PFIZER INC. $82,485.00 07/16/2024 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 1131043302
Principal investigator 1 PFIZER INC. $9,760.00 07/16/2024 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 MASTER PROTOCOL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS AT HIGH RISK OF SEVERE RSV DISEASE No dispute reported 06/30/2026 1131043391
Recipient Regeneron Pharmaceuticals, Inc. $928.34 07/16/2024 Covered Recipient Physician A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity No dispute reported 06/30/2026 1082393392
Principal investigator 1 BioNTech SE $11,754.00 07/10/2024 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1150665491
Principal investigator 1 BioNTech SE $110.97 07/10/2024 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1150665509
Principal investigator 1 BioNTech SE $132.00 07/10/2024 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1150665513
Principal investigator 1 BioNTech SE $600.00 07/10/2024 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1150665517
Principal investigator 1 BioNTech SE $474.42 07/10/2024 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1150665521
Principal investigator 1 BioNTech SE $2,387.00 07/10/2024 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1150665525
Principal investigator 1 PFIZER INC. $4,893.75 07/06/2024 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 1131042648
Principal investigator 1 BioNTech SE $5,045.00 07/02/2024 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1150665537
Principal investigator 1 Novo Nordisk AS $7.27 07/02/2024 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 1096760307
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $9,706.80 06/28/2024 Non-covered Recipient Entity
ACCELLACARE US INC
A PHASE 2 STUDY TO ASSESS THE VIROLOGIC EFFICACY OF REGN10933+REGN10987 ACROSS DIFFERENT DOSE REGIMENS IN OUTPATIENTS WITH SARS-COV-2 INFECTION No dispute reported 06/30/2026 1082430524
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $53,395.94 06/26/2024 Non-covered Recipient Entity
Pmg Research
Ph IIb dose finding vs placebo in patients with Obesity No dispute reported 06/30/2026 1101070517
Principal investigator 1 Novo Nordisk AS $23.06 06/26/2024 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 1096730360
Principal investigator 1 Novo Nordisk AS $7.27 06/26/2024 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 1096799701
Principal investigator 1 PFIZER INC. $866.11 06/26/2024 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 12 RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST VARICELLA ZOSTER VIRUS IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1131065349
Principal investigator 1 BioNTech SE $18,344.00 06/25/2024 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1150665451
Principal investigator 1 Novo Nordisk AS $1,245.99 06/21/2024 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 1096741088
Principal investigator 1 Novo Nordisk AS $343.90 06/21/2024 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9932-4954 No dispute reported 06/30/2026 1097940129
Principal investigator 1 ModernaTX, Inc. $71.55 06/20/2024 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1147191460
Principal investigator 1 BioNTech SE $22,866.00 06/18/2024 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1150665467
Principal investigator 1 Novo Nordisk AS $23.06 06/14/2024 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 1096745004
Principal investigator 1 Novo Nordisk AS $7.27 06/14/2024 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 1096833028
Principal investigator 1 Novo Nordisk AS $23.06 06/14/2024 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 1096885576
Principal investigator 1 BioNTech SE $66.00 06/13/2024 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1150665439
Principal investigator 1 BioNTech SE $20,583.00 06/11/2024 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1150665459
Principal investigator 1 Novavax Inc $20,038.00 06/10/2024 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Matrix-M1 Adjuvant in Adult Participants older than or equal to 18 Years With a Pediatric Expansion in Adolescents (12 to younger than 18 Years) No dispute reported 06/30/2026 1123378283
Principal investigator 1 Novo Nordisk AS $3,765.64 06/10/2024 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4321 No dispute reported 06/30/2026 1096882181
Principal investigator 1 Janssen Research & Development, LLC $7,136.00 06/07/2024 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3 Randomized Double-blind Controlled Study to Evaluate the Immunogenicity, Safety, and Reactogenicity of ExPEC9V and High-dose Quadrivalent Influenza Vaccine, With and Without Co-administration, in Adults Aged 65 Years or Older No dispute reported 06/30/2026 1079007604
Principal investigator 1 BioNTech SE $1,500.00 06/06/2024 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1150665469
Principal investigator 1 BioNTech SE $9,234.00 06/06/2024 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1150665479
Principal investigator 1 PFIZER INC. $176,836.80 06/06/2024 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1131059421
Principal investigator 1 Novo Nordisk AS $23.06 06/05/2024 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 1096834196
Principal investigator 1 PFIZER INC. $2,133.00 06/05/2024 Non-covered Recipient Entity
Accellacare Wilmington
A PHASE 12 RANDOMIZED DOUBLEBLIND TRIAL OF THE SAFETY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS 18 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 1130917571
Principal investigator 1 PFIZER INC. $5,116.30 06/05/2024 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1131066535
Principal investigator 1 Novo Nordisk AS $23.06 06/04/2024 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 1096771184
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $13,154.50 06/03/2024 Non-covered Recipient Entity
Accellacare-Wilmington
Phase III efficacy for obesity - without T2DM No dispute reported 06/30/2026 1138418633
Principal investigator 1 PFIZER INC. $398.94 06/01/2024 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 12 RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST VARICELLA ZOSTER VIRUS IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1131066205
Principal investigator 1 Novo Nordisk AS $600.00 05/31/2024 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4321 No dispute reported 06/30/2026 1096866856
Principal investigator 1 ModernaTX, Inc. $1,250.00 05/29/2024 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1147191458
Principal investigator 1 Novo Nordisk AS $4,629.48 05/29/2024 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 1096871466
Principal investigator 1 Novo Nordisk AS $18,224.89 05/29/2024 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9932-4954 No dispute reported 06/30/2026 1098188746
Principal investigator 1 PFIZER INC. $491,059.38 05/29/2024 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1131074320
Principal investigator 1 BioNTech SE $17,843.00 05/28/2024 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1150665485
Principal investigator 1 Novo Nordisk AS $1,250.00 05/24/2024 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4321 No dispute reported 06/30/2026 1096751859
Principal investigator 1 Novo Nordisk AS $1,512.50 05/24/2024 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4321 No dispute reported 06/30/2026 1096757159
Principal investigator 1 PFIZER INC. $72,948.10 05/24/2024 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1131074986
Principal investigator 1 BioNTech SE $930.00 05/23/2024 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1150665427
Principal investigator 1 BioNTech SE $396.00 05/23/2024 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1150665433
Principal investigator 1 BioNTech SE $393.39 05/23/2024 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1150665435
Principal investigator 1 BioNTech SE $336.00 05/23/2024 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1150665445
Principal investigator 1 BioNTech SE $1,604.15 05/23/2024 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1150665453
Principal investigator 1 BioNTech SE $66.00 05/23/2024 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1150665455
Principal investigator 1 ModernaTX, Inc. $1,000.00 05/23/2024 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1147191456
Principal investigator 1 Novo Nordisk AS $335.79 05/23/2024 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 1096884773
Principal investigator 1 BioNTech SE $9,418.00 05/21/2024 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1150665429
Principal investigator 1 BioNTech SE $71,591.00 05/21/2024 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1150665465
Principal investigator 1 BioNTech SE $14,484.00 05/14/2024 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1150665447
Principal investigator 1 BioNTech SE $8,049.00 05/14/2024 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1150665483
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $289,554.90 05/13/2024 Non-covered Recipient Entity
Pmg Research
Phase III efficacy for obesity - without T2DM No dispute reported 06/30/2026 1101070895
Principal investigator 1 Novo Nordisk AS $23.06 05/13/2024 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 1096761816
Principal investigator 1 Novo Nordisk AS $2,019.64 05/10/2024 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4578 No dispute reported 06/30/2026 1096820037
Recipient PFIZER INC. $330.00 05/07/2024 Covered Recipient Physician BNT162 CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1130898362
Principal investigator 1 PFIZER INC. $1,178.73 05/04/2024 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 12 RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST VARICELLA ZOSTER VIRUS IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1131074589
Principal investigator 1 PFIZER INC. $9,250.00 05/04/2024 Non-covered Recipient Entity
Accellacare US Inc
A STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED VACCINE CANDIDATES AGAINST INFECTIOUS RESPIRATORY ILLNESSES INCLUDING COVID19 AND RSV IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1131074980
Principal investigator 1 Novo Nordisk AS $2,831.27 04/30/2024 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 1096846313
Principal investigator 1 Novo Nordisk AS $17,828.46 04/30/2024 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9932-4954 No dispute reported 06/30/2026 1097852279
Principal investigator 1 PFIZER INC. $4,675.00 04/30/2024 Non-covered Recipient Entity
Accellacare US Inc
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 2 RANDOMIZED DOUBLEBLIND 2ARM STUDY TO INVESTIGATE A REPEAT 5DAY COURSE OF NIRMATRELVIRRITONAVIR COMPARED TO PLACEBORITONAVIR IN PARTICIPANTS AT LEAST 12 YEARS OF AGE WITH REBOUND OF COVID19 SYMPTOMS AND RAPID ANTIGEN TEST POSITIVITY No dispute reported 06/30/2026 1131088995
Principal investigator 1 Janssen Research & Development, LLC $3,568.00 04/29/2024 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3 Randomized Double-blind Controlled Study to Evaluate the Immunogenicity, Safety, and Reactogenicity of ExPEC9V and High-dose Quadrivalent Influenza Vaccine, With and Without Co-administration, in Adults Aged 65 Years or Older No dispute reported 06/30/2026 1079007596
Principal investigator 1 PFIZER INC. $1,196.82 04/26/2024 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 12 RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST VARICELLA ZOSTER VIRUS IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1131087546
Principal investigator 1 ModernaTX, Inc. $1,278.00 04/25/2024 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1147191454
Principal investigator 1 BioNTech SE $300.00 04/23/2024 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1150665473
Principal investigator 1 BioNTech SE $17,883.00 04/23/2024 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1150665487
Principal investigator 1 PFIZER INC. $3,853.35 04/19/2024 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 MASTER PROTOCOL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS AT HIGH RISK OF SEVERE RSV DISEASE No dispute reported 06/30/2026 1131089557
Principal investigator 1 BioNTech SE $19,691.00 04/16/2024 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1150665431
Principal investigator 1 Novo Nordisk AS $23.06 04/15/2024 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 1096762285
Principal investigator 1 BioNTech SE $750.00 04/12/2024 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1150665441
Principal investigator 1 BioNTech SE $750.00 04/12/2024 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1150665443
Principal investigator 1 BioNTech SE $25,072.00 04/12/2024 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1150665449
Principal investigator 1 BioNTech SE $924.00 04/12/2024 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1150665457
Principal investigator 1 BioNTech SE $66.00 04/12/2024 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1150665461
Principal investigator 1 BioNTech SE $750.00 04/12/2024 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1150665463
Principal investigator 1 BioNTech SE $132.00 04/12/2024 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1150665471
Principal investigator 1 BioNTech SE $900.00 04/12/2024 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1150665475
Principal investigator 1 BioNTech SE $300.00 04/12/2024 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1150665477
Principal investigator 1 BioNTech SE $600.00 04/12/2024 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1150665481
Principal investigator 1 BioNTech SE $300.00 04/12/2024 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1150665489
Principal investigator 1 Novo Nordisk AS $23.06 04/12/2024 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 1096814102
Principal investigator 1 PFIZER INC. $322.85 04/10/2024 Non-covered Recipient Entity
Accellacare Wilmington
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1131018504
Principal investigator 1 PFIZER INC. $916.50 04/05/2024 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 12 RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST VARICELLA ZOSTER VIRUS IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1131087714
Principal investigator 1 PFIZER INC. $4,770.36 04/05/2024 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 MASTER PROTOCOL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS AT HIGH RISK OF SEVERE RSV DISEASE No dispute reported 06/30/2026 1131089563
Principal investigator 1 PFIZER INC. $13,998.48 04/05/2024 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1131089569
Principal investigator 1 BioNTech SE $6,864.00 04/04/2024 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1150665437
Principal investigator 1 Novo Nordisk AS $23.06 04/02/2024 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 1096837615
Principal investigator 1 Janssen Research & Development, LLC $1,488.00 04/01/2024 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3 Randomized Double-blind Controlled Study to Evaluate the Immunogenicity, Safety, and Reactogenicity of ExPEC9V and High-dose Quadrivalent Influenza Vaccine, With and Without Co-administration, in Adults Aged 65 Years or Older No dispute reported 06/30/2026 1079007600
Principal investigator 1 PFIZER INC. $63,757.68 03/30/2024 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1131074425
Principal investigator 1 PFIZER INC. $19,826.60 03/29/2024 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1131077816
Principal investigator 1 PFIZER INC. $11,665.40 03/28/2024 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1131104093
Principal investigator 1 Novo Nordisk AS $23.06 03/27/2024 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 1096797399
Principal investigator 1 Novo Nordisk AS $400.00 03/27/2024 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9932-4954 No dispute reported 06/30/2026 1098215174
Principal investigator 1 Novo Nordisk AS $5,487.10 03/27/2024 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9932-4954 No dispute reported 06/30/2026 1098239113
Principal investigator 1 PFIZER INC. $5,020.23 03/27/2024 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1131104099
Principal investigator 1 Bavarian Nordic A/S $2,112.00 03/26/2024 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 1119662576
Principal investigator 1 Bavarian Nordic A/S $5,920.00 03/26/2024 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 1119662586
Principal investigator 1 Bavarian Nordic A/S $102,169.00 03/26/2024 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 1119662592
Principal investigator 1 Bavarian Nordic A/S $4,960.00 03/26/2024 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 1119662594
Principal investigator 1 Bavarian Nordic A/S $4,096.00 03/26/2024 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 1119662612
Principal investigator 1 Bavarian Nordic A/S $2,000.00 03/26/2024 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 1119662622
Principal investigator 1 Bavarian Nordic A/S $7,456.00 03/26/2024 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 1119662624
Principal investigator 1 BioNTech SE $10,686.00 03/26/2024 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1150665397
Principal investigator 1 PFIZER INC. $9,374.32 03/26/2024 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 12 RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST VARICELLA ZOSTER VIRUS IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1131077252
Principal investigator 1 Novo Nordisk AS $23.06 03/25/2024 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 1096770598
Principal investigator 1 PFIZER INC. $100.00 03/22/2024 Non-covered Recipient Entity
Accellacare US Inc
AN INTERVENTIONAL RANDOMIZED ACTIVECONTROLLED PHASE 23 STUDY TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B RNABASED VACCINE CANDIDATES AS A BOOSTER DOSE IN COVID19 VACCINEEXPERIENCED HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1131074829
Principal investigator 1 ModernaTX, Inc. $387,434.47 03/21/2024 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1147191452
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $33,412.22 03/21/2024 Non-covered Recipient Entity
ACCELLACARE US INC
A MASTER PROTOCOL ASSESSING THE SAFETY, TOLERABILITY, AND EFFICACY OF ANTI-SPIKE (S) SARS-COV-2 MONOCLONAL ANTIBODIES FOR THE TREATMENT OF AMBULATORY PATIENTS WITH COVID-19 No dispute reported 06/30/2026 1082421341
Principal investigator 1 Bavarian Nordic A/S $16,280.00 03/19/2024 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 1119662584
Principal investigator 1 Bavarian Nordic A/S $24,904.00 03/19/2024 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 1119662610
Principal investigator 1 Bavarian Nordic A/S $20,504.00 03/19/2024 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 1119662620
Principal investigator 1 Bavarian Nordic A/S $17,088.00 03/19/2024 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 1119662632
Principal investigator 1 BioNTech SE $8,444.00 03/19/2024 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1150665379
Principal investigator 1 Novo Nordisk AS $23.06 03/15/2024 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 1096839624
Principal investigator 1 Novo Nordisk AS $23.06 03/15/2024 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 1096840761
Principal investigator 1 Bavarian Nordic A/S $160.00 03/14/2024 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 1119662608
Principal investigator 1 PFIZER INC. $8,348.13 03/14/2024 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 MASTER PROTOCOL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS AT HIGH RISK OF SEVERE RSV DISEASE No dispute reported 06/30/2026 1131104384
Principal investigator 1 Bavarian Nordic A/S $22,243.00 03/12/2024 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 1119662604
Principal investigator 1 BioNTech SE $21,948.00 03/12/2024 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1150665419
Principal investigator 1 PFIZER INC. $19,500.00 03/12/2024 Non-covered Recipient Entity
Accellacare US Inc
AN INTERVENTIONAL PHASE 23 ADAPTIVE MULTICENTER RANDOMIZED DOUBLEBLIND STUDY TO INVESTIGATE EFFICACY AND SAFETY OF ORAL SISUNATOVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULTS WITH RESPIRATORY SYNCYTIAL VIRUS INFECTION WHO ARE AT RISK OF PROGRESSION TO SEVERE ILLNESS No dispute reported 06/30/2026 1131104420
Principal investigator 1 PFIZER INC. $50,597.09 03/08/2024 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1131104159
Principal investigator 1 Bavarian Nordic A/S $80.00 03/07/2024 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 1119662602
Principal investigator 1 BioNTech SE $9,927.00 03/07/2024 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1150665413
Principal investigator 1 Novo Nordisk AS $23.06 03/06/2024 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 1096808610
Principal investigator 1 Novo Nordisk AS $800.00 03/06/2024 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4578 No dispute reported 06/30/2026 1096811003
Principal investigator 1 PFIZER INC. $816.52 03/06/2024 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 2B DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED PARALLEL GROUP DOSE RANGING STUDY TO EVALUATE VIROLOGICAL RESPONSE AND SAFETY OF ORAL PF07817883 IN NONHOSPITALIZED SYMPTOMATIC ADULT PARTICIPANTS WITH COVID19 No dispute reported 06/30/2026 1130991872
Principal investigator 1 PFIZER INC. $16,700.84 03/06/2024 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 12 RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST VARICELLA ZOSTER VIRUS IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1131073499
Principal investigator 1 Novo Nordisk AS $23.06 03/05/2024 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 1096871499
Principal investigator 1 PFIZER INC. $105.50 03/05/2024 Non-covered Recipient Entity
Accellacare US Inc
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 2 RANDOMIZED DOUBLEBLIND 2ARM STUDY TO INVESTIGATE A REPEAT 5DAY COURSE OF NIRMATRELVIRRITONAVIR COMPARED TO PLACEBORITONAVIR IN PARTICIPANTS AT LEAST 12 YEARS OF AGE WITH REBOUND OF COVID19 SYMPTOMS AND RAPID ANTIGEN TEST POSITIVITY No dispute reported 06/30/2026 1131074325
Principal investigator 1 Bavarian Nordic A/S $2,376.00 02/29/2024 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 1119662578
Principal investigator 1 Bavarian Nordic A/S $6,660.00 02/29/2024 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 1119662588
Principal investigator 1 Bavarian Nordic A/S $1,057.00 02/29/2024 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 1119662598
Principal investigator 1 Bavarian Nordic A/S $5,735.00 02/29/2024 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 1119662600
Principal investigator 1 Bavarian Nordic A/S $40.00 02/29/2024 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 1119662614
Principal investigator 1 Bavarian Nordic A/S $2,220.00 02/29/2024 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 1119662616
Principal investigator 1 Bavarian Nordic A/S $2,448.00 02/29/2024 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 1119662618
Principal investigator 1 Bavarian Nordic A/S $970.00 02/29/2024 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 1119662626
Principal investigator 1 Bavarian Nordic A/S $8,388.00 02/29/2024 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 1119662628
Principal investigator 1 Bavarian Nordic A/S $13,536.00 02/29/2024 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 1119662634
Principal investigator 1 Bavarian Nordic A/S $94.00 02/29/2024 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 1119662636
Principal investigator 1 Bavarian Nordic A/S $1,032.00 02/29/2024 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 1119662638
Principal investigator 1 Bavarian Nordic A/S $94.00 02/29/2024 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 1119662918
Principal investigator 1 Bavarian Nordic A/S $530.00 02/29/2024 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 1119662920
Principal investigator 1 BioNTech SE $11,843.00 02/29/2024 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1150665421
Principal investigator 1 Novo Nordisk AS $4,534.70 02/29/2024 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 1096790072
Principal investigator 1 PFIZER INC. $32,507.50 02/29/2024 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT162B2 No dispute reported 06/30/2026 1131074431
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $895,609.33 02/29/2024 Non-covered Recipient Entity
ACCELLACARE US INC
A MASTER PROTOCOL ASSESSING THE SAFETY, TOLERABILITY, AND EFFICACY OF ANTI-SPIKE (S) SARS-COV-2 MONOCLONAL ANTIBODIES FOR THE TREATMENT OF AMBULATORY PATIENTS WITH COVID-19 No dispute reported 06/30/2026 1082419061
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140,284.13 02/29/2024 Non-covered Recipient Entity
ACCELLACARE US INC
A MASTER PROTOCOL ASSESSING THE SAFETY, TOLERABILITY, AND EFFICACY OF ANTI-SPIKE (S) SARS-COV-2 MONOCLONAL ANTIBODIES FOR THE TREATMENT OF AMBULATORY PATIENTS WITH COVID-19 No dispute reported 06/30/2026 1082419105
Principal investigator 1 Bavarian Nordic A/S $39,656.00 02/27/2024 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 1119662596
Principal investigator 1 PFIZER INC. $37,343.20 02/27/2024 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1131104508
Principal investigator 1 Janssen Research & Development, LLC $1,157.00 02/26/2024 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3 Randomized Double-blind Controlled Study to Evaluate the Immunogenicity, Safety, and Reactogenicity of ExPEC9V and High-dose Quadrivalent Influenza Vaccine, With and Without Co-administration, in Adults Aged 65 Years or Older No dispute reported 06/30/2026 1079007598
Principal investigator 1 PFIZER INC. $73,939.87 02/24/2024 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1131074331
Principal investigator 1 Novo Nordisk AS $24,809.91 02/23/2024 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9932-4954 No dispute reported 06/30/2026 1097547174
Principal investigator 1 Novo Nordisk AS $1,600.00 02/23/2024 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9932-4954 No dispute reported 06/30/2026 1098153663
Principal investigator 1 PFIZER INC. $1,000.00 02/23/2024 Non-covered Recipient Entity
Accellacare US Inc
AN INTERVENTIONAL RANDOMIZED ACTIVECONTROLLED PHASE 23 STUDY TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B RNABASED VACCINE CANDIDATES AS A BOOSTER DOSE IN COVID19 VACCINEEXPERIENCED HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1131074841
Principal investigator 1 ModernaTX, Inc. $100.00 02/22/2024 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1147191450
Principal investigator 1 BioNTech SE $693.00 02/21/2024 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1150665391
Principal investigator 1 PFIZER INC. $17,827.00 02/21/2024 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT162B2 No dispute reported 06/30/2026 1131077822
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $5,458.70 02/20/2024 Non-covered Recipient Entity
Accellacare-Wilmington
Phase III efficacy for obesity - without T2DM No dispute reported 06/30/2026 1101070897
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $7,585.00 02/19/2024 Non-covered Recipient Entity
Accellacare-Wilmington
phase III efficacy for obesity - with T2DM No dispute reported 06/30/2026 1101071835
Principal investigator 1 PFIZER INC. $150.00 02/16/2024 Non-covered Recipient Entity
ACCELLACARE
AN INTERVENTIONAL PHASE 23 ADAPTIVE MULTICENTER RANDOMIZED DOUBLEBLIND STUDY TO INVESTIGATE EFFICACY AND SAFETY OF ORAL SISUNATOVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULTS WITH RESPIRATORY SYNCYTIAL VIRUS INFECTION WHO ARE AT RISK OF PROGRESSION TO SEVERE ILLNESS No dispute reported 06/30/2026 1131093569
Principal investigator 1 PFIZER INC. $750.00 02/16/2024 Non-covered Recipient Entity
ACCELLACARE
AN INTERVENTIONAL PHASE 23 ADAPTIVE MULTICENTER RANDOMIZED DOUBLEBLIND STUDY TO INVESTIGATE EFFICACY AND SAFETY OF ORAL SISUNATOVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULTS WITH RESPIRATORY SYNCYTIAL VIRUS INFECTION WHO ARE AT RISK OF PROGRESSION TO SEVERE ILLNESS No dispute reported 06/30/2026 1131093610
Principal investigator 1 PFIZER INC. $540.00 02/16/2024 Non-covered Recipient Entity
ACCELLACARE
AN INTERVENTIONAL PHASE 23 ADAPTIVE MULTICENTER RANDOMIZED DOUBLEBLIND STUDY TO INVESTIGATE EFFICACY AND SAFETY OF ORAL SISUNATOVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULTS WITH RESPIRATORY SYNCYTIAL VIRUS INFECTION WHO ARE AT RISK OF PROGRESSION TO SEVERE ILLNESS No dispute reported 06/30/2026 1131093856
Principal investigator 1 PFIZER INC. $425.00 02/16/2024 Non-covered Recipient Entity
ACCELLACARE
AN INTERVENTIONAL PHASE 23 ADAPTIVE MULTICENTER RANDOMIZED DOUBLEBLIND STUDY TO INVESTIGATE EFFICACY AND SAFETY OF ORAL SISUNATOVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULTS WITH RESPIRATORY SYNCYTIAL VIRUS INFECTION WHO ARE AT RISK OF PROGRESSION TO SEVERE ILLNESS No dispute reported 06/30/2026 1131093861
Principal investigator 1 PFIZER INC. $6,300.00 02/16/2024 Non-covered Recipient Entity
ACCELLACARE
AN INTERVENTIONAL PHASE 23 ADAPTIVE MULTICENTER RANDOMIZED DOUBLEBLIND STUDY TO INVESTIGATE EFFICACY AND SAFETY OF ORAL SISUNATOVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULTS WITH RESPIRATORY SYNCYTIAL VIRUS INFECTION WHO ARE AT RISK OF PROGRESSION TO SEVERE ILLNESS No dispute reported 06/30/2026 1131093946
Principal investigator 1 PFIZER INC. $12,354.50 02/16/2024 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 1131104745
Principal investigator 1 Bavarian Nordic A/S $371.00 02/15/2024 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 1119662574
Principal investigator 1 Bavarian Nordic A/S $371.00 02/15/2024 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 1119662922
Principal investigator 1 PFIZER INC. $11,394.29 02/14/2024 Non-covered Recipient Entity
Accellacare US Inc
A STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED VACCINE CANDIDATES AGAINST INFECTIOUS RESPIRATORY ILLNESSES INCLUDING COVID19 AND RSV IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1131104455
Principal investigator 1 PFIZER INC. $1,000.00 02/14/2024 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 MASTER PROTOCOL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS AT HIGH RISK OF SEVERE RSV DISEASE No dispute reported 06/30/2026 1131104514
Principal investigator 1 Bavarian Nordic A/S $3,775.00 02/13/2024 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 1119662580
Principal investigator 1 Bavarian Nordic A/S $80.00 02/13/2024 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 1119662606
Principal investigator 1 Bavarian Nordic A/S $8,836.00 02/13/2024 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 1119662630
Principal investigator 1 Bavarian Nordic A/S $1,200.00 02/13/2024 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 1119662640
Principal investigator 1 Bavarian Nordic A/S $7,500.00 02/13/2024 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 1119662646
Principal investigator 1 BioNTech SE $937.00 02/13/2024 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1150665393
Principal investigator 1 BioNTech SE $1,380.84 02/13/2024 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1150665415
Principal investigator 1 BioNTech SE $300.00 02/13/2024 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1150665417
Principal investigator 1 PFIZER INC. $11,320.00 02/13/2024 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1131104153
Principal investigator 1 Novo Nordisk AS $7.27 02/09/2024 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 1096811503
Principal investigator 1 Novo Nordisk AS $23.06 02/09/2024 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 1096873851
Principal investigator 1 PFIZER INC. $24,100.00 02/08/2024 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT162B2 No dispute reported 06/30/2026 1131073530
Principal investigator 1 PFIZER INC. $7,768.79 02/08/2024 Non-covered Recipient Entity
Accellacare US Inc
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 2 RANDOMIZED DOUBLEBLIND 2ARM STUDY TO INVESTIGATE A REPEAT 5DAY COURSE OF NIRMATRELVIRRITONAVIR COMPARED TO PLACEBORITONAVIR IN PARTICIPANTS AT LEAST 12 YEARS OF AGE WITH REBOUND OF COVID19 SYMPTOMS AND RAPID ANTIGEN TEST POSITIVITY No dispute reported 06/30/2026 1131074490
Principal investigator 1 BioNTech SE $1,874.00 02/07/2024 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1150665385
Principal investigator 1 PFIZER INC. $11,041.60 02/06/2024 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 12 RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST VARICELLA ZOSTER VIRUS IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1131077247
Principal investigator 1 PFIZER INC. $362.37 02/01/2024 Non-covered Recipient Entity
Accellacare US Inc
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 2 RANDOMIZED DOUBLEBLIND 2ARM STUDY TO INVESTIGATE A REPEAT 5DAY COURSE OF NIRMATRELVIRRITONAVIR COMPARED TO PLACEBORITONAVIR IN PARTICIPANTS AT LEAST 12 YEARS OF AGE WITH REBOUND OF COVID19 SYMPTOMS AND RAPID ANTIGEN TEST POSITIVITY No dispute reported 06/30/2026 1131074788
Principal investigator 1 BioNTech SE $937.00 01/31/2024 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1150665399
Principal investigator 1 PFIZER INC. $5,450.00 01/31/2024 Non-covered Recipient Entity
Accellacare US Inc
AN INTERVENTIONAL RANDOMIZED ACTIVECONTROLLED PHASE 23 STUDY TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B RNABASED VACCINE CANDIDATES AS A BOOSTER DOSE IN COVID19 VACCINEEXPERIENCED HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1131073493
Principal investigator 1 Janssen Research & Development, LLC $55,804.00 01/29/2024 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3 Randomized Double-blind Controlled Study to Evaluate the Immunogenicity, Safety, and Reactogenicity of ExPEC9V and High-dose Quadrivalent Influenza Vaccine, With and Without Co-administration, in Adults Aged 65 Years or Older No dispute reported 06/30/2026 1079007602
Principal investigator 1 Novo Nordisk AS $2,217.68 01/29/2024 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4321 No dispute reported 06/30/2026 1096740583
Principal investigator 1 GlaxoSmithKline, LLC. $150.00 01/26/2024 Non-covered Recipient Entity
ACCELLACARE US INC
AN OPEN-LABEL MULTI-CENTRE ENABLING STUDY TO EVALUATE INFLUENZA LIKE I No dispute reported 06/30/2026 1127528172
Principal investigator 1 PFIZER INC. $25,522.75 01/26/2024 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 12 RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST VARICELLA ZOSTER VIRUS IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1131074835
Principal investigator 1 PFIZER INC. $1,400.00 01/26/2024 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 MASTER PROTOCOL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS AT HIGH RISK OF SEVERE RSV DISEASE No dispute reported 06/30/2026 1131110188
Principal investigator 1 ModernaTX, Inc. $200.00 01/25/2024 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1147191448
Principal investigator 1 PFIZER INC. $2,718.20 01/25/2024 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 MASTER PROTOCOL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS AT HIGH RISK OF SEVERE RSV DISEASE No dispute reported 06/30/2026 1131107899
Principal investigator 1 Novo Nordisk AS $962.17 01/24/2024 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 1096750754
Principal investigator 1 Novo Nordisk AS $4,837.50 01/24/2024 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 1096858290
Principal investigator 1 Novo Nordisk AS $14,911.39 01/24/2024 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9932-4954 No dispute reported 06/30/2026 1097991874
Principal investigator 1 Bavarian Nordic A/S $347.00 01/23/2024 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 1119662582
Principal investigator 1 Bavarian Nordic A/S $20,295.00 01/23/2024 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 1119662590
Principal investigator 1 Bavarian Nordic A/S $14,905.38 01/23/2024 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 1119662642
Principal investigator 1 Bavarian Nordic A/S $94.62 01/23/2024 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 1119662644
Principal investigator 1 BioNTech SE $1,386.00 01/23/2024 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1150665381
Principal investigator 1 PFIZER INC. $16,494.80 01/20/2024 Non-covered Recipient Entity
Accellacare US Inc
A STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED VACCINE CANDIDATES AGAINST INFECTIOUS RESPIRATORY ILLNESSES INCLUDING COVID19 AND RSV IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1131109773
Principal investigator 1 PFIZER INC. $276.74 01/17/2024 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 2B DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED PARALLEL GROUP DOSE RANGING STUDY TO EVALUATE VIROLOGICAL RESPONSE AND SAFETY OF ORAL PF07817883 IN NONHOSPITALIZED SYMPTOMATIC ADULT PARTICIPANTS WITH COVID19 No dispute reported 06/30/2026 1130991806
Principal investigator 1 BioNTech SE $2,811.00 01/16/2024 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1150665383
Principal investigator 1 Novo Nordisk AS $116.16 01/16/2024 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9932-4954 No dispute reported 06/30/2026 1097076165
Principal investigator 1 Novo Nordisk AS $352.20 01/16/2024 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9932-4954 No dispute reported 06/30/2026 1097094806
Principal investigator 1 Novo Nordisk AS $352.20 01/16/2024 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9932-4954 No dispute reported 06/30/2026 1097308863
Principal investigator 1 Novo Nordisk AS $352.20 01/16/2024 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9932-4954 No dispute reported 06/30/2026 1097325896
Principal investigator 1 Novo Nordisk AS $116.16 01/16/2024 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9932-4954 No dispute reported 06/30/2026 1097342530
Principal investigator 1 Novo Nordisk AS $352.20 01/16/2024 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9932-4954 No dispute reported 06/30/2026 1097369037
Principal investigator 1 Novo Nordisk AS $352.20 01/16/2024 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9932-4954 No dispute reported 06/30/2026 1097550795
Principal investigator 1 Novo Nordisk AS $352.20 01/16/2024 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9932-4954 No dispute reported 06/30/2026 1097608573
Principal investigator 1 Novo Nordisk AS $352.20 01/16/2024 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9932-4954 No dispute reported 06/30/2026 1097727247
Principal investigator 1 Novo Nordisk AS $116.16 01/16/2024 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9932-4954 No dispute reported 06/30/2026 1097887682
Principal investigator 1 Novo Nordisk AS $116.16 01/16/2024 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9932-4954 No dispute reported 06/30/2026 1097909084
Principal investigator 1 Novo Nordisk AS $352.20 01/16/2024 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9932-4954 No dispute reported 06/30/2026 1097934371
Principal investigator 1 Novo Nordisk AS $352.20 01/16/2024 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9932-4954 No dispute reported 06/30/2026 1097971582
Principal investigator 1 Novo Nordisk AS $352.20 01/16/2024 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9932-4954 No dispute reported 06/30/2026 1098002442
Principal investigator 1 Novo Nordisk AS $352.20 01/16/2024 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9932-4954 No dispute reported 06/30/2026 1098092797
Principal investigator 1 Novo Nordisk AS $116.16 01/16/2024 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9932-4954 No dispute reported 06/30/2026 1098113122
Principal investigator 1 Novo Nordisk AS $352.20 01/16/2024 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9932-4954 No dispute reported 06/30/2026 1098193164
Principal investigator 1 Novo Nordisk AS $352.20 01/16/2024 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9932-4954 No dispute reported 06/30/2026 1098201736
Principal investigator 1 Novo Nordisk AS $352.20 01/16/2024 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9932-4954 No dispute reported 06/30/2026 1098201810
Principal investigator 1 Novo Nordisk AS $352.20 01/16/2024 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9932-4954 No dispute reported 06/30/2026 1098231556
Principal investigator 1 Novo Nordisk AS $7.27 01/15/2024 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 1096802074
Principal investigator 1 Novo Nordisk AS $23.06 01/15/2024 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 1096874474
Principal investigator 1 GlaxoSmithKline, LLC. $38,926.80 01/12/2024 Non-covered Recipient Entity
ACCELLACARE US INC
AN OPEN-LABEL MULTI-CENTRE ENABLING STUDY TO EVALUATE INFLUENZA LIKE I No dispute reported 06/30/2026 1127551092
Principal investigator 1 Novo Nordisk AS $23.06 01/12/2024 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 1096718969
Principal investigator 1 Novo Nordisk AS $7.27 01/12/2024 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 1096808813
Principal investigator 1 PFIZER INC. $5,891.00 01/11/2024 Non-covered Recipient Entity
Accellacare US Inc
A STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED VACCINE CANDIDATES AGAINST INFECTIOUS RESPIRATORY ILLNESSES INCLUDING COVID19 AND RSV IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1131107031
Principal investigator 1 GlaxoSmithKline, LLC. $4,846.05 01/10/2024 Non-covered Recipient Entity
ACCELLACARE US INC
A PHASE 3, OBSERVER-BLIND, RANDOMIZED, PLACEBO CONTROLLED STUDY TO EVA No dispute reported 06/30/2026 1127528174
Principal investigator 1 BioNTech SE $693.00 01/09/2024 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1150665387
Principal investigator 1 GlaxoSmithKline, LLC. $72,172.98 01/09/2024 Non-covered Recipient Entity
ACCELLACARE US INC
A PHASE 1/2, RANDOMIZED, DOSE-FINDING/DOSE-CONFIRMATION STUDY TO EVALU No dispute reported 06/30/2026 1127515818
Principal investigator 1 PFIZER INC. $5,045.98 01/06/2024 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 12 RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST VARICELLA ZOSTER VIRUS IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1131076617
Principal investigator 1 BioNTech SE $675.35 01/05/2024 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1150665389
Principal investigator 1 BioNTech SE $488.00 01/05/2024 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1150665395
Principal investigator 1 BioNTech SE $600.00 01/05/2024 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1150665401
Principal investigator 1 BioNTech SE $2,618.00 01/05/2024 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1150665403
Principal investigator 1 BioNTech SE $300.00 01/05/2024 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1150665405
Principal investigator 1 BioNTech SE $750.00 01/05/2024 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1150665407
Principal investigator 1 BioNTech SE $300.00 01/05/2024 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1150665409
Principal investigator 1 BioNTech SE $6,000.00 01/05/2024 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1150665411
Principal investigator 1 BioNTech SE $600.00 01/05/2024 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1150665423
Principal investigator 1 BioNTech SE $240.00 01/05/2024 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1150665425
Principal investigator 1 GlaxoSmithKline, LLC. $1,000.00 01/05/2024 Non-covered Recipient Entity
ACCELLACARE US INC
AN OPEN-LABEL MULTI-CENTRE ENABLING STUDY TO EVALUATE INFLUENZA LIKE I No dispute reported 06/30/2026 1127522856
Principal investigator 1 Novo Nordisk AS $23.06 01/02/2024 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 1096848664
Principal investigator 1 Boehringer Ingelheim International GmbH $13,741.89 01/01/2024 Non-covered Recipient Entity
Accellacare-Wilmington
phase III efficacy for obesity - with T2DM No dispute reported 06/30/2026 1101067879
Principal investigator 1 Boehringer Ingelheim International GmbH $14,031.18 01/01/2024 Non-covered Recipient Entity
Accellacare-Wilmington
Phase III efficacy for obesity - without T2DM No dispute reported 06/30/2026 1101068913